Phase II study of irinotecan+5FU/FA for patients with previously treated advanced gastric cancer.

被引：0
|
作者：
Peeters, M
Van Laethem, JL
Baert, F
Canon, JL
De Grève, J
Kalantari, H
Dhont, P
Van Cutsem, E
机构：
[1] State Univ Ghent Hosp, B-9000 Ghent, Belgium
[2] Erasme Univ Hosp, B-1070 Brussels, Belgium
[3] H Hart Hosp, Roeselare, Belgium
[4] Clin Notre Dame, Charleroi, Belgium
[5] Univ Brussels, Acad Ziekenhuis, Ghent, Belgium
[6] Ctr Hosp Peltzer La Tourelle, Verviers, Belgium
[7] Aventis Pharma, Brussels, Belgium
[8] Katholieke Univ Leuven, Hosp Gasthuisberg, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4076
引用
收藏
页码：332S / 332S
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.
    Schmitt, C
    Levy-Piedbois, C
    Frappé, M
    Durand-Zaleski, I
    Gruia, G
    Alakl, M
    Rougier, P
    ANNALS OF ONCOLOGY, 2000, 11 : 47 - 47
  • [2] A randomized phase II study of biweekly irinotecan versus irinotecan plus 5-fluorouracil/leucovor in combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer.
    Sym, S.
    Park, Y.
    Park, S.
    Park, J.
    Cho, E.
    Lee, W.
    Chung, M.
    Shin, D.
    Lee, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase II trial of oxaliplatin, 5-FU, and leucovorin chemotherapy for the previously treated patients with advanced gastric cancer
    Oh, S. C.
    Kim, Y.
    Kim, J.
    Choi, I.
    Sung, H.
    Seo, H.
    Shin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase II study of marimastat in patients with previously treated advanced lung cancer.
    Nakagawa, K
    Fukuoka, M
    CLINICAL CANCER RESEARCH, 1999, 5 : 3774S - 3774S
  • [5] A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
    Sun Jin Sym
    Heung Moon Chang
    Hye Jin Kang
    Sung Sook Lee
    Min-Hee Ryu
    Jae-Lyun Lee
    Tae-Won Kim
    Jeong Hwan Yook
    Sung Tae Oh
    Byung Sik Kim
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 1 - 8
  • [6] A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
    Sym, Sun Jin
    Chang, Heung Moon
    Kang, Hye Jin
    Lee, Sung Sook
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Kim, Tae-Won
    Yook, Jeong Hwan
    Oh, Sung Tae
    Kim, Byung Sik
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 1 - 8
  • [7] Phase I trial of cisplatin, infusional 5-FU and irinotecan in advanced gastric cancer.
    Seguru, A
    Fernández-Martos, C
    Aparicio, J
    Campos, JM
    Vicent, J
    Busquier, I
    Molins, C
    Guillem, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 156S - 156S
  • [8] A RANDOMIZED PHASE II STUDY OF BIWEEKLY IRINOTECAN VERSUS IRINOTECAN PLUS 5-FLUOROURACIL/LEUCOVORIN AS A SALVAGE CHEMOTHERAPY IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED GASTRIC CANCER
    Sym, S.
    Park, Y.
    Park, S.
    Park, J.
    Cho, E.
    Lee, W.
    Chung, M.
    Shin, D.
    Lee, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 25 - 25
  • [9] Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer.
    Enzinger, PC
    Clark, J
    Ryan, D
    Meyerhardt, J
    Kulke, M
    Fidias, P
    Earle, C
    Vincitore, M
    Michelini, A
    Fuchs, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 323S - 323S
  • [10] Results of the phase II portion of a phase I/II study of pemetrexed plus irinotecan in patients with advanced colorectal cancer previously treated with a 5-fluorouracil (5-FU)-containing regimen
    Kettner, Erika
    Kroening, Hendrik
    Hochster, Howard
    Becker, Klaus
    Peschel, Christian
    Ramanathan, Ramesh K.
    Macdonald, Jack
    Hong, Shengyan
    John, Bill
    Schmoll, Hans-Joachim
    ANNALS OF ONCOLOGY, 2004, 15 : 85 - 86
12345